K-Bio Value Report

[카테고리:] New Drug Development

  • Alteogen

    Alteogen is evolving from a platform provider into a global biopharmaceutical powerhouse. Its strategy is anchored by the Hybrozyme (ALT-B4) platform, which is currently the only global competitor to Halozyme’s technology, alongside a high-value biosimilar and ADC pipeline. 1. Hybrozyme (ALT-B4): The SC Conversion Engine Alteogen’s core moat is Hybrozyme, a proprietary human recombinant hyaluronidase…

  • Hanmi Pharm

    Hanmi Pharm

    1. LAPSCOVERY™: The Verified Bio-Platform Hanmi’s core technical advantage is the LAPSCOVERY™ (Long-Acting Protein/Peptide Discovery) technology. LAPSCOVERYTM Long Acting Protein / Peptide Discovery Platform Technology Overview  Biologics have a short half-life when administered to the human body. This results in the need for frequent injections and inconvenience to patients. LAPSCOVERYTM (Long Acting Protein/Peptide Discovery) is a platform technology that…

  • LigaChem Bio

    LigaChem Bio

    * ADC (Antibody-Drug Conjugate) background The “Smart Bomb” or “Guided Missile” for cancer. For those new to the world of biotechnology, ADC (Antibody-Drug Conjugate) can be understood through a very simple and powerful analogy: the “Smart Bomb” or “Guided Missile” for cancer. Traditionally, chemotherapy was like a “grenade”—it killed cancer cells, but it also damaged…

  • ABL Bio

    ABL Bio

    Technological Evolution: The “Grabody” Roadmap The company’s R&D strategy has evolved across three distinct generations of innovation. Phase 1: The “Grabody” Platform Foundation Initial focus was on mastering Bispecific Antibodies, which target two different antigens simultaneously to increase efficacy and reduce toxicity. Phase 2: Global Validation of the BBB Shuttle (2022–2025) The focus shifted to…